Geron price target lowered to $4.50 from $5 at Baird

Baird lowered the firm’s price target on Geron to $4.50 from $5 and keeps an Outperform rating on the shares. The firm views the stock as particularly attractive to own near-term, as they believe it’s likely the upcoming FDA AdCom meeting will end with a favorable vote.